Clinical trial: The combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 8, 2010, Pages 1000-1006

  Furnari, M ^a   Parodi, A ^a   Gemignani, L ^a   Giannini, E G ^a   Marenco, S ^a   Savarino, E ^a   Assandri, L ^a   Fazio, V ^a   Bonfanti, D ^a   Inferrera, S ^a   Savarino, V ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GUAR GUM; RIFAXIMIN;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BREATH ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SMALL INTESTINAL BACTERIAL OVERGROWTH; SMALL INTESTINE DISEASE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT WITHDRAWAL;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BREATH TESTS; FEMALE; GALACTANS; GASTROINTESTINAL AGENTS; GLUCOSE; HUMANS; INTESTINE, SMALL; MALE; MANNANS; MIDDLE AGED; PLANT GUMS; QUESTIONNAIRES; RIFAMYCINS;

EID: 77957234858     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04436.x     Document Type: Article

References (46)

1. Husebye E. The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy 2005 51: 1 22. (Pubitemid 40663186)
2. Gregg CR. Enteric bacterial flora and bacterial overgrowth syndrome. Semin Gastrointest Dis 2002 13: 200 209.
3. Sherman P, Lichtman S. Small bowel bacterial overgrowth syndrome. Dig Dis 1987 5: 157 171.
4. Bouhnik Y, Alain S, Attar A, et al. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol 1999 94: 1327 1331. (Pubitemid 29214649)
5. Henriksson AE, Blomquist L, Nord CE, et al. Small intestinal bacterial overgrowth in patients with rheumatoid arthritis. Ann Rheum Dis 1993 52: 503 510. (Pubitemid 23227214)
6. Drenick EJ, Johnson D. Hepatic steatosis after intestinal bypass-prevention and reversal metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology 1982 82: 535 548. (Pubitemid 12166814)
7. Parodi A, Paolino S, Greco A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol 2008 6: 759 764.
8. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004 292: 852 858. (Pubitemid 39079672)
9. Parodi A, Dulbecco P, Savarino E, et al. Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. J Clin Gastroenterol 2009 43: 962 966.
10. Pimentel M, Park S, Mirocha J, et al. The effect of nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006 145: 557 563. (Pubitemid 46780934)
11. Posserud I, Stotzer PO, Björnsson ES, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007 56: 802 808. (Pubitemid 46854194)
12. Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systemic review and meta-analysis. Clin Gastroenterol Hepatol 2009 7: 1279 1286.
13. Grover M, Kanazawa M, Palsson OS, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: association with colon motility, bowel symptoms, and psychological distress. Neurogastroenterol Motil 2008 20: 998 1008.
14. Corazza GR, Menozzi MG, Strocchi A, et al. The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology 1990 98: 302 309. (Pubitemid 20037910)
15. Peralta S, Cottone C, Doveri T, et al. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with rifaximin. World J Gastroenterol 2009 15: 2628 2631.
16. Parodi A, Capurso G, Perri F, et al. H2-breath testing for small-intestinal bacterial overgrowth. Aliment Pharmacol Ther 2009 29 (Suppl. 1 18 26.
17. Majewski M, McCallum RW, Sostarich S, et al. Efficacy of rifaximin, a nonabsorbed oral antiobiotic, in the treatment of small intestinal bacterial overgrowth. Am J Med Sci 2007 333: 266 270. (Pubitemid 46787954)
18. Lauritano EC, Gabrielli M, Lupascu A, et al. Rifaximin dose finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005 22: 31 5. (Pubitemid 40943872)
19. Scarpellini E, Gabrielli M, Lauritano CE, et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2007 25: 781 786. (Pubitemid 46434913)
20. Pimentel M. Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs 2009 18: 349 358.
21. Parodi A, Sessarego M, Greco A, et al. Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am J Gastroenterol 2008 103: 1257 1262. (Pubitemid 351677970)
22. Ellen L. Bacterial overgrowth. In: Yamada T, Alpers DH, Kaplowitz N, Laine L, Owyang C, Powel DW (eds). Textbook of Gastroenterology. 4th edn. Philadelphia: JB Lippincott, 2003: Vol. 2, 1617 1625.
23. Resmini E, Parodi A, Savarino V, et al. Evidence of prolonged orocecal transit time and small intestinal bacterial overgrowth in acromegalic patients. J Clin Endocrinol Metab 2007 92: 2119 2124. (Pubitemid 46997109)
24. Lauritano EC, Bilotta AL, Gabrielli M, et al. Association between hypothyroidsm ans small intestinal bacterial overgrowth. J Clin Endocrinol Metab 2007 92: 4180 4184. (Pubitemid 350074729)
25. Latella G, Pimpo MT, Sottili S, et al. Rifaximin improbe symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 2003 18: 55 62. (Pubitemid 36764140)
26. Papi C, Ciaco A, Koch M, et al. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo controlled trial. Aliment Pharcol Ther 1995 3: 33 9.
27. Di Mario F, Aragona G, Leandro G, et al. Efficacy of mesalaxine in the treatment of symptomatic diverticular disease. Dig Dis Sci 2005 50: 581 586. (Pubitemid 40543752)
28. Lauritano EC, Gabrielli M, Scarpellini E, et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci 2009 13: 111 116.
29. Muller-Lissner SA. Effect of wheat bran on weight of stool and gastrointestinal transit time: a meta-analysis. Br Med J 1988 296: 615 617. (Pubitemid 18059446)
30. Stephen AM, Cummings JH. Mechanism of action of dietary fibre in the human colon. Nature 1980 284: 283 284. (Pubitemid 10112057)
31. Bijkerk CJ, Muris JW, Knottnerus JA, et al. Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004 19: 245 251.
32. Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: time for a reappraisal. Lancet 1994 344: 39 40. (Pubitemid 24199426)
33. Lina BAR. Sub-Chronic (13 Week) Oral Toxicity Study With Sunfiber and Sunfiber ST in Rats. TNO report V97.080. Amsterdam: TNO Nutrition and Food Research Institute, 1997.
34. Takahashi H, Yamamoto T. Effect of partially hydrolyzed guar gum on fecal output in human volunteers. Nutr Res 1993 13: 649 657. (Pubitemid 23150603)
35. Giaccari S, Grasso G, Tronci S, et al. Gomma guar parzialmente idrolizzata: una fibra come coadiuvante nella sindrome del colon irritabile. Clin Ter 2001 152: 21 5. (Pubitemid 32417134)
36. Giannini EG, Mansi C, Dulbecco P, et al. Role of partially hydrolyzed guar gum in the treatment of irritable bowel syndrome. Nutrition 2006 22: 334 342. (Pubitemid 43261533)
37. Takahashi H, Yamamoto T. Influence of partially hydrolyzed guar gum on constipation in women. J Nutr Sci Vitaminol 1994 40: 251 257. (Pubitemid 24236669)
38. Tuohy KM, Gibson GR. The prebiotic effects of biscuits containing partially hydrolyzed guar gum and fructo-oligosaccharides-a human volunteer study. Br J Nutr 2001 86: 341 348.
39. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microflora-introducing the concept of prebiotics. J Nutr 1995 125: 1401 1412.
40. Weaver GA, Tangel C, Krause JA, et al. Dietary guar gum alters colonic microbial fermentation in azoxymethane-treated rats. J Nutr 1996 126: 1979 1981. (Pubitemid 26260219)
41. Okubo T, Ishihara T, Takahashi H, et al. Effects of partially hydrolyzed guar gum intake on human intestinal microflora and its metabolism. Biosci Biotechnol Biochem 1994 58: 1364 1369. (Pubitemid 2146302)
42. Lupp C, Robertson ML, Wickham ME, et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2007 2: 204. (Pubitemid 47209521)
43. Philips SF. Physiology and pathophysiology of the colon: relationship to constipation. In: Barbara L, Stanghellini V, eds. Chronic Constipation. London: WB Saunders 1996, pp. 19 37.
44. Riordan SM, McIver CJ, Walker BM, et al. The lactulose breath hydrogen test and small intestinal bacterial overgrowth. Am J Gastroenterol 1996 91: 1795 1803. (Pubitemid 26307185)
45. Rocco A, De Martino G, De Nucci G, et al. Intra-individual reproducibility of the glucose hydrogen breath test in a cohort of healthy subjects. Dig Liver Dis 2010 42 (Suppl. 2 118.
46. Lombardo L, Foti M, Ruggia O, et al. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010 8: 504 508.